

Future Directions in Acute Myeloid Leukemia: An OncLive Scientific Workshop and Interchange

Objectives

- Describe and discuss challenges surrounding the management of acute myeloid leukemia (AML) in the relapsed or refractory setting
- Review data on the current standard of care and identify the current gaps in care and unmet needs
- Evaluate the potential role for novel agents in clinical trials, including how to incorporate into therapeutic sequencing strategies
- Insights on the treatment for NPM1 mutant, KMT2A-r and MEIS1-high AML patients
- Obtain expert feedback on menin-MLL inhibitors in development and understand how they may inform the treatment paradigm for adult patients with R/R AML
- Identify potential trials of interest involving novel therapies and combinations in AML